NASDAQ:ELOX Eloxx Pharmaceuticals Q2 2026 Earnings Report $16.00 +0.56 (+3.63%) As of 03:59 PM Eastern ProfileEarnings HistoryForecast Eloxx Pharmaceuticals EPS ResultsActual EPS-$0.66Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEloxx Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEloxx Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/11/2026TimeAfter Market ClosesConference Call DateTuesday, August 11, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Eloxx Pharmaceuticals Earnings HeadlinesEloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Receives Consensus Rating of "Buy" from AnalystsSeptember 23 at 3:47 AM | americanbankingnews.comEloxx Pharmaceuticals (ELOX) vs. Its Peers Financial AnalysisSeptember 21 at 7:45 AM | americanbankingnews.comShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.September 24 at 1:00 AM | Digest Publishing (Ad)Eloxx Pharmaceuticals (ELOX) & Its Rivals Financial ComparisonSeptember 21 at 6:45 AM | americanbankingnews.comHead to Head Review: Eloxx Pharmaceuticals (ELOX) versus Its RivalsSeptember 20, 2026 | americanbankingnews.comFinancial Contrast: Eloxx Pharmaceuticals (ELOX) vs. Its RivalsSeptember 17, 2026 | americanbankingnews.comSee More Eloxx Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eloxx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eloxx Pharmaceuticals and other key companies, straight to your email. Email Address About Eloxx PharmaceuticalsEloxx Pharmaceuticals (NASDAQ:ELOX) was a clinical-stage biopharmaceutical company focused on developing therapies for genetic diseases caused by nonsense mutations, which can prevent cells from producing functional proteins. The company’s research platform centered on ribosome modulation, an approach intended to encourage cells to read through certain premature stop signals in genetic instructions. Its lead product candidate, ELX-02, was an investigational small-molecule therapy designed to promote the production of full-length proteins in diseases associated with nonsense mutations. Eloxx evaluated ELX-02 primarily for cystinosis, a rare inherited disorder caused by mutations in the CTNS gene, and also explored potential applications in other genetic conditions, including cystic fibrosis. The company was formerly known as Zikani Therapeutics and conducted research and development activities in the United States and Israel, including work through its Israeli operations. Eloxx was a development-stage company and did not have an established portfolio of marketed products. Public information about its later operations and leadership is limited, and the company’s status changed substantially after its development programs were advanced.View Eloxx Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
